Cytotoxicity of ((E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one)) on HeLa cell line

  • Adisty Ridha Damasuri Shcool of Medicine,
  • Eti Nurwening Sholikhah Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
  • Mustofa Department of Pharmacology and Therapy, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta
Keywords: chalcone, mtc 7, hela, vero, cytotoxicity

Abstract

In our previous study, some amino chalcone derivatives have been synthesized and evaluated their cytotoxicity against breast cancer cell line T47D. Among 11 amino chalcone derivatives, ((E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one)) exhibited the most active compound.This study aimed to investigate cytotoxic activity of the ((E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one)) against cervical cell line (HeLa). The cytotoxic activitywas determined using the MTT colorimetric assay. Cisplatin was used as positive control. From this MTT method, inhibitory concentration 50% (IC50) values were determined by probit analysis based on the relationship between log concentrations versus the percentage of cells growth inhibition.The results showed that the IC50 of ((E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one)) and cisplatinwere 22.75 ± 19.13 μg/mL and 14.96±1.08 μg/mL, respectively. In conclusion, the ((E)-1-(4-aminophenyl)-3-phenylprop-2-en-1-one)) has moderate cytotoxic activity against HeLa cell line based on National Cancer Institute (NCI) criteria.

References

Mattiuzzi1 C & Lippi G. Current cancer epidemiology. J Epidemiol Global Health 2019; 9(4):217-22.

https://doi.org/10.2991/jegh.k.191008.001

Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in2018: a worldwide analysis. Lancet Global Health 2020; 8: e191-203.

https://doi.org/10.1016/S2214-109X(19)30482-6

ICO/IARC Information Centre on HPV and Cancer. Indonesia: human papillomavirus and related cancers, fact sheet 2018.

Available from: https://hpvcentre.net/statistics/ reports/IDN_FS.pdf

Nuranna L, Aziz MF, Cornain S, Purwoto G, Purbadi S, Budiningsih S, et al. Cervical cancer prevention program in Jakarta, Indonesia: see and treat model in developing country. J Gynecol Oncol 2012; 23(3):147-52.

https://doi.org/10.3802/jgo.2012.23.3.147

Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation. Gynecol Oncol 2014; 135(2):208-12.

https://doi.org/10.1016/j.ygyno.2014.08.018

Zhang GL, Jiang L, Yan Q, Liu RH, Zhang L. Anti-tumor effect of matrine combined with cisplatin on rat models of cervical cancer. Asian Pac J Trop Med 2015; 8(12):1055-9.

https://doi.org/10.1016/j.apjtm.2015.11.005

Fidalgo AR, Saldaña SM, Trinidad A, Alonso BO, Valiente AR, Berrocal JRG, et al. In vitro and in vivo effects of lutein against cisplatin-induced ototoxicity. Exp Toxicol Pathol 2016; 68(4):197-204.

https://doi.org/10.1016/j.etp.2016.01.003

Wang Y, Gao Y, Cheng H, Yang G, Tan W. Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer. BiochemBiophys Res Commun 2015; 466(3):362-8.

https://doi.org/10.1016/j.bbrc.2015.09.029

Suwito H, Kristanti AN, Nyoman N, Puspaningsih T. Chalcones: synthesis, structure diversity and pharmacological aspects. J Chem Pharm Res 2014; 6(5):1076-88.

Suwito H, Jumina, Mustofa, Ni’matuzahroh, Puspaningsih, NNT.Anticancer and antimicrobial activity of methoxy amino chalcone derivatives. Der Pharma Chemica, 2015, 7(3):89-94.

Zhang EH, Wang RF, Guo SZ, Liu B. An update on antitumor activity of naturally occurring chalcones. Evid Based Complement Alternat Med 2013; 2013:815621.

https://doi.org/10.1155/2013/815621

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2):55-63.

https://doi.org/10.1016/0022-1759(83)90303-4

Sajjadi SE, Ghanadian M, Haghighi M, Mouhebat L. Cytotoxic effect of Cousiniaver bascifolia bunge against OVCAR-3 and HT-29 cancer cells. J Her Med Pharmacol 2015; 4(1):15-9.

Zhao L, Mao L, Hong G, Yang X, Liu T. Design, synthesis and anticancer activity of matrine–1H-1,2,3-triazole–chalcone conjugates. Bioorg Med Chem Lett 2015; 25(12):2540-4.

https://doi.org/10.1016/j.bmcl.2015.04.051

Orlikova B, Tasdemir D, Golais F, Dicato M, Diederich M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr 2011; 6(2):125-47.

https://doi.org/10.1007/s12263-011-0210-5

Jandial DD, Blair CA, Zhang S, Krill LS, Zhang YB, Zi X. Molecular targeted approaches to cancer therapy and prevention using chalcones. Curr Cancer Drug Targets 2014; 14(2):181-200.

https://doi.org/10.2174/1568009614666140122160515

Published
2020-12-31
Section
Articles